RE:RE:RE:Egrifta Patent Situation
TH is not different than any other pharma or cie. They will boost their expectations as they did with Egrifta when they were talking about a 30 000 market for their product. Same for Trogarzo. Their study suggested that doctors would clearly prescribe Trogarzo to their patient, everything in the survey was more than positive. Not saying they did wrong, they are just doing what all other such cie will do, providing to high expectations. And they will do it again with new product. So talking about NASH and answering questions is nice to give investors some hope so why not. Sometime they (we) will win, most of the time they wont. Biotech and pharma is a risky business and we all know that. I will still hang on to Trogarzo to bring revenues to TH and let those reel numbers to talk. That is the only way SP can increase steadily. :o)